| Name | sodium,(2R)-2-[[(2R)-2-amino-3-(1-methoxycarbonylindol-3-yl)propanoyl]-[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]hexanoate |
|---|---|
| Synonyms |
DMpc-gaMMa-MeLeu-D-Trp(1-CO2CH3)-D-Nle.Na (DMpc : cis-2,6-DiMethylpiperidinocbonyl)
sodium,(2R)-2-[[(2R)-2-amino-3-(1-methoxycbonylindol-3-yl)propanoyl]-[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]hexanoate BQ 788 2,6-Dimethylpiperidinecbonyl-γ-Methyl-Leu-Nin-(Methoxycbonyl)-D-Trp-D-Nle D-Norleucine, N-[[(2R,6S)-2,6-dimethyl-1-piperidinyl]carbonyl]-4-methyl-L-leucyl-1-(methoxycbonyl)-D-tryptophyl-, sodium salt (1:1) N-[N-[N-[(2,6-Dimethyl-1-piperidinyl)carbonyl]-4-methyl-L-leucyl]-1-(methoxycbonyl)-D-tryptophyl]-D-norleucine sodium salt Sodium (R)-2-((R)-2-((S)-2-((2R,6S)-2,6-dimethylpiperidine-1-cboxamido)-4,4-dimethylpentanamido)-3-(1-(methoxycbonyl)-1H-indol-3-yl)propanamido)hexanoate 1-ELAIDYLPHOSPHOCHOLINE N-[(cis-2,6-Dimethyl-1-piperidinyl)carbonyl]-4-methyl-L-leucyl-1-(methoxycbonyl)-D-tryptophyl-D-norleucinesodiumsalt MFCD00797882 BQ-788 SYNTHETIC ETB ENDOTHELIN REC T N-cis-2,6-dimethylpiperidinocbonyl-L-γMeLeu-D-Trp(COOMe)-D-Nle-ONa BQ-788 SODIUM BQ-788 sodium salt BQ789 Sodium Salt BQ 788 sodium salt, ETB rector antagonist N-[N-[N-[(2,6-Dimethyl-1-piperidinyl)carbonyl] BQ788 SODIUM SALT; BQ 788 SODIUM SALT N-[N-[N-[(2,6-Dimethyl-1-piperidinyl)carbonyl]-4-methyl-L-leucyl]-1-(methoxycbonyl)-D-tryptophyl]-D-norleucine sodium salt, 2,6-Dimethylpiperidinecbonyl-γ-Methyl-Leu-Nin-(Methoxycbonyl)-D-Trp-D-Nle |
| Description | BQ-788 (sodium salt) is a potent and selective ETB receptor antagonist, inhibiting ET-1 binding to ETB receptors with an IC50 of 1.2 nM in human Girrardi heart cells. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.2 nM (ETB) |
| In Vitro | BQ-788 potently and competitively inhibits 125I-labeled ET-1 binding to ETB receptors in human Girrardi heart cells (hGH) with an IC50 of 1.2 nM, but only poorly inhibits the binding to ETA receptors in human neuro-blastoma cell line SK-N-MC cells (IC50, 1300 nM). BQ-788 shows no agonistic activity up to 10 μM and competitively inhibits thevasoconstriction induced by an ETB-selective agonist (pA2, 8.4). BQ-788 also inhibits several bioactivities of ET-1, such as bronchoconstriction, cell proliferation, and clearance of perfused ET-1[1]. |
| In Vivo | BQ-788 (3 mg/kg/h, i.v.) completely inhibits a pharmacological dose of ET-1- or sarafotoxin6c (0.5 nmol/kg, i.v.)-induced ETB receptor-mediated depressor, but not pressor responses in conscious rats. Furthermore, BQ-788 markedly increases the plasma concentration of ET-1, which is considered an index of potential ETB receptor blockade in vivo. In Dahl salt-sensitive hypertensive (DS) rats, BQ-788 (3 mg/kg/h, i.v.) increases blood pressure by about 20 mm Hg. It is reported that BQ-788 also inhibits ET-1-induced bronchoconstriction, tumor growth and lipopolysaccharide-induced organfailure[1]. BQ 788 (3 mg/kg) results in an eightfold leftward shift in the ET-1 dose-response curve, suggesting a significant involvement of ETB dilator receptors[2]. Mice are treated with 30 nmol BQ-788 by intraplantar, reduce mechanical hyperalgesia (47% and 42%), thermal hyperalgesia (68% and 76%), oedema (50% and 30%); myeloperoxidase activity (64% and 32%), and overt-pain like behaviours. Additionally, intraplantar treatment with clazosentan or BQ-788 decreases spinal (45% and 41%) and peripheral (47% and 47%) superoxide anion production as well as spinal (47% and 47%) and peripheral (33% and 54%) lipid peroxidation, respectively[3]. |
| References |
| Molecular Formula | C34H50N5NaO7 |
|---|---|
| Molecular Weight | 663.78000 |
| Exact Mass | 663.36100 |
| PSA | 161.90000 |
| LogP | 4.59590 |
| Storage condition | 2-8℃ |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| HS Code | 2923900090 |
| HS Code | 2923900090 |
|---|---|
| Summary | 2923900090 other quaternary ammonium salts and hydroxides。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:6.5%。General tariff:30.0% |